This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schantz, E J
Right arrow Articles by Johnson, E A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schantz, E J
Right arrow Articles by Johnson, E A

 Previous Article  |  Next Article 

Microbiol Mol Biol Rev. 1992 March; 56(1): 80-99

Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

E J Schantz and E A Johnson

Department of Food Microbiology, University of Wisconsin, Madison 53706.

SUMMARY

Crystalline botulinum toxin type A was licensed in December 1989 by the Food and Drug Administration for treatment of certain spasmodic muscle disorders following 10 or more years of experimental treatment on human volunteers. Botulinum toxin exerts its action on a muscle indirectly by blocking the release of the neurotransmitter acetylcholine at the nerve ending, resulting in reduced muscle activity or paralysis. The injection of only nanogram quantities (1 ng = 30 mouse 50% lethal doses [U]) of the toxin into a spastic muscle is required to bring about the desired muscle control. The type A toxin produced in anaerobic culture and purified in crystalline form has a specific toxicity in mice of 3 x 10(7) U/mg. The crystalline toxin is a high-molecular-weight protein of 900,000 Mr and is composed of two molecules of neurotoxin (ca. 150,000 Mr) noncovalently bound to nontoxic proteins that play an important role in the stability of the toxic unit and its effective toxicity. Because the toxin is administered by injection directly into neuromuscular tissue, the methods of culturing and purification are vital. Its chemical, physical, and biological properties as applied to its use in medicine are described. Dilution and drying of the toxin for dispensing causes some detoxification, and the mouse assay is the only means of evaluation for human treatment. Other microbial neurotoxins may have uses in medicine; these include serotypes of botulinum toxins and tetanus toxin. Certain neurotoxins produced by dinoflagellates, including saxitoxin and tetrodotoxin, cause muscle paralysis through their effect on the action potential at the voltage-gated sodium channel. Saxitoxin used with anaesthetics lengthens the effect of the anaesthetic and may enhance the effectiveness of other medical drugs. Combining toxins with drugs could increase their effectiveness in treatment of human disease.

Microbiol Mol Biol Rev. 1992 March; 56(1): 80-99




This article has been cited by other articles:

  • Poras, H., Ouimet, T., Orng, S.-V., Fournie-Zaluski, M.-C., Popoff, M. R., Roques, B. P. (2009). Detection and Quantification of Botulinum Neurotoxin Type A by a Novel Rapid In Vitro Fluorimetric Assay. Appl. Environ. Microbiol. 75: 4382-4390 [Abstract] [Full Text]  
  • Chen, Y., Korkeala, H., Linden, J., Lindstrom, M. (2008). Quantitative Real-Time Reverse Transcription-PCR Analysis Reveals Stable and Prolonged Neurotoxin Cluster Gene Activity in a Clostridium botulinum Type E Strain at Refrigeration Temperature. Appl. Environ. Microbiol. 74: 6132-6137 [Abstract] [Full Text]  
  • Yang, G. C., Chiu, R. J., Gillman, G. S. (2008). Questioning the Need to Use Botox Within 4 Hours of Reconstitution: A Study of Fresh vs 2-Week-Old Botox. Arch Facial Plast Surg 10: 273-279 [Abstract] [Full Text]  
  • Partikian, A., Mitchell, W. G. (2007). Iatrogenic Botulism in a Child With Spastic Quadriparesis. J Child Neurol 22: 1235-1237 [Abstract]  
  • Eubanks, L. M., Hixon, M. S., Jin, W., Hong, S., Clancy, C. M., Tepp, W. H., Baldwin, M. R., Malizio, C. J., Goodnough, M. C., Barbieri, J. T., Johnson, E. A., Boger, D. L., Dickerson, T. J., Janda, K. D. (2007). An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 104: 2602-2607 [Abstract] [Full Text]  
  • Maddaloni, M., Staats, H. F., Mierzejewska, D., Hoyt, T., Robinson, A., Callis, G., Kozaki, S., Kiyono, H., McGhee, J. R., Fujihashi, K., Pascual, D. W. (2006). Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A. J. Immunol. 177: 5524-5532 [Abstract] [Full Text]  
  • Sharma, S. K., Ferreira, Joseph. L., Eblen, B. S., Whiting, R. C. (2006). Detection of Type A, B, E, and F Clostridium botulinum Neurotoxins in Foods by Using an Amplified Enzyme-Linked Immunosorbent Assay with Digoxigenin-Labeled Antibodies. Appl. Environ. Microbiol. 72: 1231-1238 [Abstract] [Full Text]  
  • Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swerdlow, D. L., Tonat, K., for the Working Group on Civilian Biodefense, (2001). Botulinum Toxin as a Biological Weapon: Medical and Public Health Management. JAMA 285: 1059-1070 [Abstract] [Full Text]  
  • Vaezi, M F, Richter, J E, Wilcox, C M, Schroeder, P L, Birgisson, S, Slaughter, R L, Koehler, R E, Baker, M E (1999). Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 44: 231-239 [Abstract] [Full Text]  
  • Cornille, F., Deloye, F., Fournié-Zaluski, M.-C., Roques, B. P., Poulain, B. (1995). Inhibition of Neurotransmitter Release by Synthetic Proline-rich Peptides Shows That the N-terminal Domain of Vesicle-associated Membrane Protein/Synaptobrevin Is Critical for Neuro-exocytosis. J. Biol. Chem. 270: 16826-16832 [Abstract] [Full Text]  
  • Kouguchi, H., Watanabe, T., Sagane, Y., Sunagawa, H., Ohyama, T. (2002). In Vitro Reconstitution of the Clostridium botulinum Type D Progenitor Toxin. J. Biol. Chem. 277: 2650-2656 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»